132 related articles for article (PubMed ID: 26299666)
1. Differential Gene Expression of BRCA1,ERBB2 and TP53 biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer.
Zghair AN; Sinha DK; Kassim A; Alfaham M; Sharma AK
Anticancer Agents Med Chem; 2016; 16(4):519-25. PubMed ID: 26299666
[TBL] [Abstract][Full Text] [Related]
2. Increased TNF α, IL-6 and ErbB2 mRNA expression in peripheral blood leukocytes from breast cancer patients.
Alokail MS; Al-Daghri NM; Mohammed AK; Vanhoutte P; Alenad A
Med Oncol; 2014 Aug; 31(8):38. PubMed ID: 24961464
[TBL] [Abstract][Full Text] [Related]
3. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
[TBL] [Abstract][Full Text] [Related]
4. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
[TBL] [Abstract][Full Text] [Related]
5. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
Holstege H; Horlings HM; Velds A; Langerød A; Børresen-Dale AL; van de Vijver MJ; Nederlof PM; Jonkers J
BMC Cancer; 2010 Nov; 10():654. PubMed ID: 21118481
[TBL] [Abstract][Full Text] [Related]
6. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
[TBL] [Abstract][Full Text] [Related]
8. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
9. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance.
Santarpia M; Altavilla G; Margeli M; Cirauqui B; Mesiti M; Cavallari V; Ramirez JL; Sanchez-Ronco M; Santarpia L; Taron M; Rosell R
Cancer Invest; 2008 Dec; 26(10):1044-51. PubMed ID: 18798071
[TBL] [Abstract][Full Text] [Related]
11. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
Adem C; Soderberg CL; Hafner K; Reynolds C; Slezak JM; Sinclair CS; Sellers TA; Schaid DJ; Couch F; Hartmann LC; Jenkins RB
Genes Chromosomes Cancer; 2004 Sep; 41(1):1-11. PubMed ID: 15236312
[TBL] [Abstract][Full Text] [Related]
12. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
13. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 Promoter Methylation and Clinicopathological Characteristics in Sporadic Breast Cancer Patients in Indonesia.
Harahap WA; Sudji IR; Nindrea RD
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2643-2649. PubMed ID: 30256562
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
Otis CN; Krebs PA; Albuquerque A; Quezado MM; San Juan X; Sobel ME; Merino MJ
Int J Surg Pathol; 2002 Oct; 10(4):237-45. PubMed ID: 12490973
[TBL] [Abstract][Full Text] [Related]
16. Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.
Gallenne T; Ross KN; Visser NL; Salony ; Desmet CJ; Wittner BS; Wessels LFA; Ramaswamy S; Peeper DS
Oncotarget; 2017 Mar; 8(13):20572-20587. PubMed ID: 28411283
[TBL] [Abstract][Full Text] [Related]
17. Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women.
Wang Y; Lin L; Li L; Wen J; Chi Y; Hao R; Dai X; Chen Y; Huang D; Zhou Y; You J; Ye Z; Chen H; Jin L; Chen D; Yang F; Xia E; Ma X; Guo F; Tong Y; Zheng M; Wang O
Aging (Albany NY); 2021 Apr; 13(8):11860-11876. PubMed ID: 33893247
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and TP53 Gene-Mutations: Family Predisposition and Radioecological Risk of Developing Breast Cancer.
Apsalikov B; Manambaeva Z; Ospanov E; Massabayeva M; Zhabagin K; Zhagiparova Z; Maximov V; Voropaeva E; Apsalikov K; Belikhina T; Abdrahmanov R; Cherepkova E; Tanatarov S; Massadykov A; Urazalina N
Asian Pac J Cancer Prev; 2016; 17(8):4059-62. PubMed ID: 27644661
[TBL] [Abstract][Full Text] [Related]
19. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
20. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
